These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7735174)

  • 1. In vitro and in vivo evaluation of streptavidin immunoconjugates of the second generation TAG-72 monoclonal antibody CC49.
    Ngai WM; Reilly RM; Polihronis J; Shpitz B
    Nucl Med Biol; 1995 Jan; 22(1):77-86. PubMed ID: 7735174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin.
    Alvarez-Diez TM; Polihronis J; Reilly RM
    Nucl Med Biol; 1996 May; 23(4):459-66. PubMed ID: 8832700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin.
    Domingo RJ; Reilly RM
    Nucl Med Commun; 2000 Jan; 21(1):89-96. PubMed ID: 10717908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
    Foulon CF; Bigner DD; Zalutsky MR
    Bioconjug Chem; 1999; 10(5):867-76. PubMed ID: 10502355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49.
    Tang Y; Yang S; Gariépy J; Scollard DA; Reilly RM
    Bioconjug Chem; 2007; 18(3):677-84. PubMed ID: 17361988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
    Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.
    Zou P; Xu S; Povoski SP; Wang A; Johnson MA; Martin EW; Subramaniam V; Xu R; Sun D
    Mol Pharm; 2009; 6(2):428-40. PubMed ID: 19718796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
    Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
    Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trans-cyclooctene tag with improved properties for tumor pretargeting with the diels-alder reaction.
    Rossin R; van Duijnhoven SM; Läppchen T; van den Bosch SM; Robillard MS
    Mol Pharm; 2014 Sep; 11(9):3090-6. PubMed ID: 25077373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
    Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
    Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor activity of CC49-doxorubicin immunoconjugates.
    Johnson DA; Briggs SL; Gutowski MC; Barton R
    Anticancer Res; 1995; 15(4):1387-93. PubMed ID: 7654026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A robust method for the preparation and purification of antibody/streptavidin conjugates.
    Hylarides MD; Mallett RW; Meyer DL
    Bioconjug Chem; 2001; 12(3):421-7. PubMed ID: 11353541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate.
    DePalatis LR; Frazier KA; Cheng RC; Kotite NJ
    Cancer Res; 1995 Nov; 55(22):5288-95. PubMed ID: 7585590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
    Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ
    Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.